Why Short-Seller Andrew Left Is Bullish on Palantir Rival Databricks
To say Andrew Left has had an eventful past decade in the market would be an understatement. He burst onto the scene as a short-seller extraordinaire. As the founder of Citron Research, he made his name with a series of reports on Valeant Pharmaceuticals in 2015, which he called the “pharmaceutical Enron.” The company ended…